Northwoods NETS is pleased to announce that Senator Mark Dayton has proclaimed Friday, November 10th, NET Cancer Awareness Day in the state of Minnesota. We thank Governor Dayton for his continued recognition of this unusual cancer. It is estimated that approximately 300 Minnesotans are diagnosed with each year with this poorly understood disease. NETS, also known as neuroendocrine tumors, are considered rare tumors that have either benign or malignant behaviors.
The National Comprehensive Cancer Network (NCCN) has recently released a new guideline book for patients diagnosed with neuroendocrine tumors. With very readable language it discusses what neuroendocrine tumors are, how they are diagnosed, the various types of treatments that are available based on the location your neuroendocrine tumor was found, and treatment decisions. Also included in this guide is a dictionary to easily look up terms related to neuroendocrine tumors,
After years of randomized trials and nearly two decades of European data detailing peptide receptor radionuclide therapy, Advanced Accelerator Applications (AAA), a Novartis company, is pleased to announced that the FDA has approved the use of this therapy for patients with neuroendocrine tumors. The approval comes at a time when incidence of neuroendocrine cancers of the pancreas, lungs, and intestines are on the rise. About 7 in 100,000 people are
On January 14, 2018, Dr. Thor Halfdanarson and Dr. A. Tuba Kendi from Mayo Clinic Rochester presented to Northwoods NETS. Dr. Tuba, a radiologist from Mayo, has been fronting the Gallium-68 PET/MRI scan center that has been helping detect and diagnose neuroendocrine tumor patients. She is now at the forefront the PRRT (peptide receptor radionuclide therapy) at the Rochester clinic. Dr. Thor presented his vision for the newly designated Neuroendocrine
Happy New Year to all of our NET patients, caregivers, family members, medical support teams and friends around the world. Twenty eighteen is going to be a fantastic year!